

MYRIAD GENETICS INC  
Form 8-K  
October 22, 2008

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 10/20/2008**

**Myriad Genetics, Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 0-26642**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**87-0494517**  
(IRS Employer  
Identification No.)

**320 Wakara Way**  
Salt Lake City, Utah 84108  
(Address of principal executive offices, including zip code)

**801-584-3600**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On October 20, 2008, Myriad Genetics, Inc. (the Company) announced that its Board of Directors has authorized management to proceed with preparations to spin off its research and drug development businesses from its molecular diagnostics business. It is anticipated that the proposed spin-off will be completed as a pro-rata dividend distribution to shareholders of the Company.

The press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits**

(d) The following exhibit is filed with this report:

Exhibit

Number Description

99.1 The Registrant's press release dated October 20, 2008.

---

**Signature(s)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Myriad Genetics, Inc.

Date: October 21, 2008

By: /s/ Peter D. Meldrum

---

Peter D. Meldrum  
President and Chief Executive Officer

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	The Registrant's press release dated October 20, 2008.